公开(公告)号：US08877967B2

公开(公告)日：2014-11-04

申请号：US13786142

申请日：2013-03-05

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary Lynn Trawick

IPC分类号： C07C337/08

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

摘要翻译： 本发明涉及式I化合物和使用这些化合物治疗组织蛋白酶，特别是组织蛋白酶K或组织蛋白酶L的调节将在治疗上有用的条件的方法。

公开(公告)号：US20150031915A1

公开(公告)日：2015-01-29

申请号：US14505165

申请日：2014-10-02

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary L. Trawick

IPC分类号： C07C337/08 ,  C07C49/786

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

摘要翻译： 本发明涉及式I化合物和使用这些化合物治疗组织蛋白酶，特别是组织蛋白酶K或组织蛋白酶L的调节将在治疗上有用的条件的方法。

公开(公告)号：USRE45907E1

公开(公告)日：2016-03-01

申请号：US14180238

申请日：2014-02-13

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Charles Manly Garner, III ,  Robert Ronald Kane ,  Kevin G. Pinney ,  Joseph Anthony Prezioso ,  Klaus Edvardsen

IPC分类号： A01N57/00 ,  C07C43/23 ,  C07C45/63 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07F9/12 ,  C07C237/04 ,  C07C47/575

CPC分类号： C07C43/23 ,  C07C45/63 ,  C07C47/575 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07C237/04 ,  C07F9/12

摘要： Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

公开(公告)号：US20130296605A1

公开(公告)日：2013-11-07

申请号：US13786142

申请日：2013-03-05

申请人： OXIGENE, INC. ,  BAYLOR UNIVERSITY

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary L. Trawick

IPC分类号： C07C337/08

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

公开(公告)号：US09458103B2

公开(公告)日：2016-10-04

申请号：US14505165

申请日：2014-10-02

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary L. Trawick

IPC分类号： C07C337/08 ,  C07C49/786

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

公开(公告)号：USRE45720E1

公开(公告)日：2015-10-06

申请号：US14180209

申请日：2014-02-13

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Charles Manly Garner, III ,  Robert Ronald Kane ,  Kevin G. Pinney ,  Joseph Anthony Prezioso ,  Klaus Edvardsen

IPC分类号： C07C207/00 ,  C07C207/04 ,  C07C205/37 ,  C07C205/00 ,  C07C217/00 ,  C07C237/00 ,  C07C217/84 ,  C07C237/04 ,  C07C43/00 ,  C07C45/63 ,  C07C43/23 ,  C07F9/00 ,  C07C9/12 ,  C07C47/575 ,  C07F9/12

CPC分类号： C07C43/23 ,  C07C45/63 ,  C07C47/575 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07C237/04 ,  C07F9/12

摘要： Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

公开(公告)号：US20200055805A1

公开(公告)日：2020-02-20

申请号：US16542869

申请日：2019-08-16

申请人： Baylor University

发明人： Kevin G. Pinney ,  Haichan Niu ,  Deboprosad Mondal

IPC分类号： C07C43/23 ,  C07C49/755 ,  A61P35/00

摘要： A series of benzosuberene analogues demonstrate effective inhibition of tubulin polymerization, cytotoxicity against human cancer cell lines, and vascular disruption in tumors.

公开(公告)号：US20190010173A1

公开(公告)日：2019-01-10

申请号：US15752487

申请日：2016-08-12

申请人： Mateon Therapeutics, Inc. ,  Baylor University

发明人： Kevin G. Pinney ,  Mary Lynn Trawick ,  Erica N. Parker ,  David J. Chaplin

IPC分类号： C07F9/06 ,  A61K31/661 ,  A61K45/06

摘要： This present disclosure is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin L, cathepsin K, and/or cathepsin B, will be therapeutically useful. Formula I: or a solvate or pharmaceutically acceptable salt thereof. Each of R1-R10 are independently selected from the group consisting of: hydrogen, alkoxy, halo, hydroxy, phosphate, phosphate salts, disodium phosphate, diphosphate dimer, diphosphate dimer salt, and sodium diphosphate dimer with at least one of R1-R10 is a phosphate or diphosphate dimer group.

公开(公告)号：US09873668B2

公开(公告)日：2018-01-23

申请号：US15253504

申请日：2016-08-31

申请人： Mateon Therapeutics, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Kishore Kumar Gaddale Devanna ,  Erica Parker ,  Kevin G. Pinney ,  Jiangli Song ,  Mary Lynn Trawick

IPC分类号： C07C337/08 ,  C07C49/786

CPC分类号： C07C337/08 ,  C07C49/786

摘要： This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

公开(公告)号：US10807932B2

公开(公告)日：2020-10-20

申请号：US16542869

申请日：2019-08-16

申请人： Baylor University

发明人： Kevin G. Pinney ,  Haichan Niu ,  Deboprosad Mondal

IPC分类号： C07C43/23 ,  C07C49/755 ,  A61P35/00

摘要： A series of benzosuberene analogues demonstrate effective inhibition of tubulin polymerization, cytotoxicity against human cancer cell lines, and vascular disruption in tumors.